A detailed history of Driehaus Capital Management LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 603,397 shares of RARE stock, worth $20 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
603,397
Previous 606,407 0.5%
Holding current value
$20 Million
Previous $22 Million 17.68%
% of portfolio
0.15%
Previous 0.21%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$26.31 - $41.44 $79,193 - $124,734
-3,010 Reduced 0.5%
603,397 $18.2 Million
Q2 2025

Aug 14, 2025

SELL
$31.06 - $39.3 $7.65 Million - $9.68 Million
-246,250 Reduced 28.88%
606,407 $22 Million
Q1 2025

May 15, 2025

BUY
$36.21 - $45.78 $839,782 - $1.06 Million
23,192 Added 2.8%
852,657 $30.9 Million
Q4 2024

Feb 14, 2025

BUY
$42.07 - $57.72 $1.92 Million - $2.63 Million
45,521 Added 5.81%
829,465 $34.9 Million
Q3 2024

Nov 14, 2024

BUY
$40.21 - $59.36 $10.3 Million - $15.2 Million
255,764 Added 48.42%
783,944 $43.5 Million
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $5.2 Million - $7.17 Million
138,889 Added 35.68%
528,180 $21.7 Million
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $1.3 Million - $1.62 Million
30,125 Added 8.39%
389,291 $18.2 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $4.38 Million - $6.78 Million
137,920 Added 62.34%
359,166 $17.2 Million
Q3 2023

Nov 14, 2023

SELL
$34.92 - $46.66 $3.79 Million - $5.06 Million
-108,422 Reduced 32.89%
221,246 $7.89 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $12.3 Million - $17.2 Million
329,668 New
329,668 $15.2 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.32B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.